Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Krystal Biotech filings document formal disclosures for a commercial-stage biotechnology company developing and commercializing genetic medicines. Recent 8-K reports furnish quarterly and annual financial results, VYJUVEK net product revenue updates, Regulation FD clinical materials, FDA-related program updates, and commercial launch information for VYJUVEK in Japan.
The company's proxy materials disclose board and shareholder-vote matters, executive compensation, equity awards, ownership information, and governance practices. Together, the filings record how Krystal reports operating performance, capital resources, pipeline and regulatory disclosures, and public-company governance for its HSV-1-based gene therapy platform.
Krystal Biotech, Inc. executive vice president and general counsel Thomas John Charles sold 642 shares of common stock in an open-market transaction. The shares were sold at an average price of $302.03 per share on May 26, 2026, and his directly held common stock position reported in this filing is now zero shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, which is scheduled to run through December 31, 2026 unless it terminates earlier under its terms.
Krystal Biotech, Inc. reported results of its 2026 annual stockholder meeting held on May 15, 2026. Stockholders elected Class III directors Krish S. Krishnan and Christopher Mason for three-year terms, each receiving over 22 million votes in favor with additional broker non-votes recorded.
Stockholders also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with over 28.4 million votes for and minimal opposition. In a non-binding advisory vote, stockholders approved named executive officer compensation for 2025, and unaffiliated stockholders approved the company’s Non-Employee Director Compensation Policy after excluding directors and certain litigation defendants from voting on that item.
Krystal Biotech insiders Krish S. Krishnan and Suma M. Krishnan jointly filed Amendment No. 3 to their Schedule 13G/A reporting an aggregate 3,388,283 shares of Common Stock, representing 11.5% of the class. The percentage is based on 29,479,756 shares outstanding as of April 29, 2026. The filing breaks down holdings as directly owned shares, shares held in family and spousal trusts, and stock options exercisable for 158,525 and 121,350 shares respectively. The Reporting Persons state shared voting and dispositive power over the aggregate amount and include a Joint Filing Agreement as Exhibit 99.1.
Krystal Biotech reported strong first quarter 2026 results, driven by VYJUVEK gene therapy sales and advancing its genetic medicine pipeline. VYJUVEK net product revenue reached $116.4 million in Q1 2026, a 32% increase over the prior-year quarter, with a gross margin of 95%.
Net income rose to $55.9 million, or $1.83 per diluted share, compared with $35.7 million, or $1.20 per diluted share, in Q1 2025. The company ended the quarter with a $1.0 billion cash and investment balance, supporting ongoing commercial and R&D activities.
Management highlighted global VYJUVEK uptake, including over 695 U.S. reimbursement approvals and growing European use, alongside multiple late-stage programs. Two ophthalmology registrational readouts are anticipated in 2026, and the FDA granted platform technology designation for KB407 and KB111, reinforcing the company’s HSV-1-based gene therapy platform.
Krystal Biotech, Inc. reported strong profitability for the quarter ended March 31, 2026, driven by rapid uptake of its gene therapy VYJUVEK. Product revenue, net rose to $116.4 million from $88.2 million a year earlier, largely from growth in Europe and Japan.
Gross margin was 95%, while net income increased to $55.9 million from $35.7 million. Diluted net income per share was $1.83, up from $1.20. Cash, cash equivalents and short-term investments totaled about $823.4 million, and the company reported retained earnings of $80.1 million, highlighting a solid balance sheet to fund its expanding clinical pipeline across ophthalmology, respiratory, dermatology, oncology and aesthetics.
Krystal Biotech Inc ownership filing: Vanguard Portfolio Management reports beneficial ownership of 1,479,111 shares of Common Stock, representing 5.05% of the class. The filing states Vanguard has sole dispositive power over 1,479,111 shares and sole voting power for 22,384 shares.
The disclosure attributes holdings to Vanguard Portfolio Management and identified affiliates and notes these positions include shares held for Vanguard funds and managed accounts.
Krystal Biotech, Inc. reports a full-year Form 10-K describing a commercial-stage gene therapy company that launched its first approved product, VYJUVEK, in the U.S. (2023) and expanded launches to Europe and Japan in 2025. The report highlights $730.3 million in cumulative net product revenue since U.S. launch, global regulatory approvals and an advanced pipeline including inhaled KB407 for cystic fibrosis and inhaled KB707 for NSCLC. The company operates two in‑house CGMP facilities, reports an aggregate market value of common stock held by non-affiliates of $3.5 billion as of June 30, 2025, and had 29,232,189 shares outstanding as of February 11, 2026.
The filing details clinical progress across multiple programs, regulatory designations (ODD, RPDD, RMAT, FDA platform designation), commercialization status, manufacturing scale-up, and known program risks summarized under "Risk Factors."